Form 13-F position report

PSYCHEMEDICS CORP

Reported by GEODE CAPITAL MANAGEMENT LLC

PMDI CUSIP 744375205 Manager CIK 0001214717

Reported 0 shares, down 42,679 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q4 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 47 Through Q4 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 240000
2022-03-31 240000
2022-06-30 223000
2022-09-30 227000
2022-12-31 173000
2023-03-31 184831
2023-06-30 160539
2023-09-30 145350
2023-12-31 108367
2024-03-31 109057
2024-06-30 90075
2024-09-30 98624
2024-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for PSYCHEMEDICS CORP held by GEODE CAPITAL MANAGEMENT LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2024 Reduced 0 -42,679 (-100.0%) 0 $0 2025-02-12
Q3 2024 Added 42,679 +5,474 (14.7%) < 0.01% $98,624 2024-11-12
Q2 2024 Unchanged 37,205 0 (0.0%) < 0.01% $90,075 2024-08-09
Q1 2024 Added 37,205 +609 (1.7%) < 0.01% $109,057 2024-05-13
Q4 2023 Unchanged 36,596 0 (0.0%) < 0.01% $108,367 2024-02-13
Q3 2023 Added 36,596 +1,390 (3.9%) < 0.01% $145,350 2023-11-13
Q2 2023 Unchanged 35,206 0 (0.0%) < 0.01% $160,539 2023-08-11
Q1 2023 Unchanged 35,206 0 (0.0%) < 0.01% $184,831 2023-05-15
Q4 2022 Reduced 35,206 -98 (-0.3%) < 0.01% $173,000 2023-02-13
Q3 2022 Unchanged 35,304 0 (0.0%) < 0.01% $227,000 2022-11-14
Q2 2022 Added 35,304 +686 (2.0%) < 0.01% $223,000 2022-08-12
Q1 2022 Unchanged 34,618 0 (0.0%) < 0.01% $240,000 2022-05-13
Q4 2021 Unchanged 34,618 0 (0.0%) < 0.01% $240,000 2022-02-11
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

22 managers reported PSYCHEMEDICS CORP for Q4 2024.

Managers reporting PSYCHEMEDICS CORP in Q4 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
SANTA MONICA PARTNERS LP Unchanged 20,000 0 0.02% $45,000 17 qtrs
CALDWELL SUTTER CAPITAL INC Reduced 0 -250 0 $0 7 qtrs
MORGAN STANLEY Reduced 0 -3,001 0 $0 47 qtrs
VANGUARD GROUP INC Reduced 0 -251,283 0 $0 47 qtrs
CITADEL ADVISORS LLC Reduced 0 -21,509 0 $0 6 qtrs
DIMENSIONAL FUND ADVISORS LP Reduced 0 -21,060 0 $0 47 qtrs
ADVISOR GROUP HOLDINGS INC Reduced 0 -257 0 $0 3 qtrs
GEODE CAPITAL MANAGEMENT LLC This report Reduced 0 -42,679 0 $0 47 qtrs
WEDBUSH SECURITIES INC Reduced 0 -47,868 0 $0 10 qtrs
Provenance Wealth Advisors LLC Reduced 0 -772 0 $0 6 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2024
Filed
February 12, 2025
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.